The LUX-Lung clinical trials further focused on a second-generation EGFR-TKI, afatinib, performing a comprehensive survey of treatment effects in patients with advanced EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.